Introducing Lung Cancer Detection Test (LCDT1™)

LCDT1 is a simple blood test that evaluates protein biomarkers in patient samples and leverages the power of our propriety machine learning algorithm to detect earlystage Non-Small Cell Lung Cancer (NSCLC) with 95% accuracy. The accessibility and affordability of this test will improve lung cancer patient outcomes and lead to a better quality of life. The use of the LCDT1 aims to make early detection accessible and affordable for all. TargetDx is committed to enhancing the journey and quality of life for lung cancer patients because every moment matters, and a brighter, healthier future awaits.

Lung Cancer: The World’s Deadliest Cancer

Lung cancer is the leading cause of cancer death worldwide. Over 238,340 of new diagnosis and 127,070 lung cancer deaths are estimated for 2023 in the United States.

Early detection is crucial when it comes to treating lung cancer. The survival rate of lung cancer is high when caught and treated at the earliest stage. However, most cases of lung cancer are undetected until it is too late.


Click on the video to learn more about our test.

TargetDX Laboratory

TargetDx Laboratory, located in Valparaiso, Indiana, is a medical device company dedicated to creating a groundbreaking blood test for the early detection of Non-Small Cell Lung Cancer (NSCLC). Our test, developed using a combination of protein biomarkers and proprietary machine learning algorithms delivers a highly sensitive and specific risk assessment for early-stage lung cancer.

Our choice to focus on protein markers is rooted in their ability to reflect the physiological state of tissue, giving us a real-time picture of the interplay between genetics and the environment. This focus has not only led to the discovery of novel markers linked to lung cancer but has also allowed us to validate existing markers for diagnostic use, culminating in multiple patents and research publications.

The pinnacle of our innovation is the Lung Cancer Detection Test 1 (LCDT1), a simple blood test with a notable ~95% accuracy for detecting Stage 1 lung cancer. With LCDT1, we aim to transform lung cancer detection, facilitating earlier intervention and enhancing the quality of life for patients. Our mission is to transform lung cancer screening focusing on early, precise detection to dramatically reduce the cancer's impact. We aim to provide hope for a future with a substantially lesser burden of cancer, improving both survival and the quality of life for those affected.